"Lilly's pipeline remains incapable of replacing patent-related losses."
Within an AP report titled Lilly pitches plan to overcome key patent losses, one has the text:
Bernstein analyst Dr. Tim Anderson said in a note Lilly's pipeline remains incapable of replacing patent-related losses. He projects annual sales of the antipsychotic Zyprexa, Lilly's top seller, to fall from $5 billion last year to about $1.4 billion by 2020.
Lilly loses U.S. patent protection for Zyprexa in October. In the next two years, the drugmaker will lose U.S. patents protecting drugs that produced 46 percent of its 2010 revenue.
**In passing, one might ask "what happened" to the inventors of Epogen and of Lipitor (not Lilly products, but relevant to a general theme here)? Outside the drug world, what happened to the inventor of Exxon's thermal de-NOx?
Bernstein analyst Dr. Tim Anderson said in a note Lilly's pipeline remains incapable of replacing patent-related losses. He projects annual sales of the antipsychotic Zyprexa, Lilly's top seller, to fall from $5 billion last year to about $1.4 billion by 2020.
Lilly loses U.S. patent protection for Zyprexa in October. In the next two years, the drugmaker will lose U.S. patents protecting drugs that produced 46 percent of its 2010 revenue.
**In passing, one might ask "what happened" to the inventors of Epogen and of Lipitor (not Lilly products, but relevant to a general theme here)? Outside the drug world, what happened to the inventor of Exxon's thermal de-NOx?
posted by Lawrence B. Ebert at 4:01 AM
0 Comments:
Post a Comment
<< Home